Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.08
CTIC's Cash to Debt is ranked higher than
63% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CTIC: 4.08 )
CTIC' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 4.08

Equity to Asset 0.45
CTIC's Equity to Asset is ranked higher than
58% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CTIC: 0.45 )
CTIC' s 10-Year Equity to Asset Range
Min: -2.06   Max: 0.94
Current: 0.45

-2.06
0.94
F-Score: 3
Z-Score: -28.11
M-Score: -0.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -143.54
CTIC's Operating margin (%) is ranked higher than
68% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CTIC: -143.54 )
CTIC' s 10-Year Operating margin (%) Range
Min: -123250   Max: -119.75
Current: -143.54

-123250
-119.75
Net-margin (%) -155.41
CTIC's Net-margin (%) is ranked higher than
67% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CTIC: -155.41 )
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75   Max: -123.26
Current: -155.41

-169773.75
-123.26
ROE (%) -330.82
CTIC's ROE (%) is ranked lower than
52% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CTIC: -330.82 )
CTIC' s 10-Year ROE (%) Range
Min: -520.3   Max: -42.02
Current: -330.82

-520.3
-42.02
ROA (%) -121.84
CTIC's ROA (%) is ranked higher than
50% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CTIC: -121.84 )
CTIC' s 10-Year ROA (%) Range
Min: -261.37   Max: -20.35
Current: -121.84

-261.37
-20.35
ROC (Joel Greenblatt) (%) -1529.23
CTIC's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CTIC: -1529.23 )
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2180.72   Max: -48.38
Current: -1529.23

-2180.72
-48.38
EBITDA Growth (3Y)(%) -29.40
CTIC's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CTIC: -29.40 )
CTIC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -71.5   Max: 50.1
Current: -29.4

-71.5
50.1
EPS Growth (3Y)(%) -43.10
CTIC's EPS Growth (3Y)(%) is ranked higher than
56% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CTIC: -43.10 )
CTIC' s 10-Year EPS Growth (3Y)(%) Range
Min: -74.4   Max: 64
Current: -43.1

-74.4
64
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CTIC Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

CTIC Guru Trades in Q2 2014

Jim Simons 692,650 sh (New)
» More
Q3 2014

CTIC Guru Trades in Q3 2014

Jim Simons 1,010,871 sh (+45.94%)
» More
Q4 2014

CTIC Guru Trades in Q4 2014

Jim Simons 587,916 sh (-41.84%)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.10
CTIC's P/B is ranked higher than
58% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CTIC: 8.10 )
CTIC' s 10-Year P/B Range
Min: 5.71   Max: 122
Current: 8.1

5.71
122
P/S 4.85
CTIC's P/S is ranked higher than
86% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CTIC: 4.85 )
CTIC' s 10-Year P/S Range
Min: 0.06   Max: 40559.92
Current: 4.85

0.06
40559.92
Current Ratio 2.22
CTIC's Current Ratio is ranked higher than
60% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CTIC: 2.22 )
CTIC' s 10-Year Current Ratio Range
Min: 0.42   Max: 17.35
Current: 2.22

0.42
17.35
Quick Ratio 2.10
CTIC's Quick Ratio is ranked higher than
61% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CTIC: 2.10 )
CTIC' s 10-Year Quick Ratio Range
Min: 0.42   Max: 17.28
Current: 2.1

0.42
17.28
Days Inventory 1.00
CTIC's Days Inventory is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CTIC: 1.00 )
CTIC' s 10-Year Days Inventory Range
Min: 16.31   Max: 8925.18
Current: 1

16.31
8925.18
Days Sales Outstanding 12.22
CTIC's Days Sales Outstanding is ranked higher than
96% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CTIC: 12.22 )
CTIC' s 10-Year Days Sales Outstanding Range
Min: 2.47   Max: 1460
Current: 12.22

2.47
1460

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.30
CTIC's Price/Net Cash is ranked higher than
69% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. CTIC: 16.30 )
CTIC' s 10-Year Price/Net Cash Range
Min: 11.94   Max: 7208.47
Current: 16.3

11.94
7208.47
Price/Net Current Asset Value 14.00
CTIC's Price/Net Current Asset Value is ranked higher than
70% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. CTIC: 14.00 )
CTIC' s 10-Year Price/Net Current Asset Value Range
Min: 6.84   Max: 1182.11
Current: 14

6.84
1182.11
Price/Tangible Book 8.20
CTIC's Price/Tangible Book is ranked higher than
65% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. CTIC: 8.20 )
CTIC' s 10-Year Price/Tangible Book Range
Min: 4.19   Max: 1492
Current: 8.2

4.19
1492
Earnings Yield (Greenblatt) -29.30
CTIC's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CTIC: -29.30 )
CTIC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -34.1   Max: 0
Current: -29.3

-34.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0QUJ.UK, CTIC.Italy, CEPR.Germany,
CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is engaged in commercializing PIXUVRI (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May 2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
comment on CTIC Dec 16 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Our Partners
What Makes CTI BioPharma (CTIC) a Strong Sell? - Tale of the Tape Mar 26 2015 - ZACKS

More From Other Websites
CTI BioPharma to Report First Quarter 2015 Financial Results on May 6, 2015 Apr 23 2015
CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be... Apr 22 2015
CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be... Apr 22 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Mar 31 2015
What Makes CTI BioPharma (CTIC) a Strong Sell? - Tale of the Tape Mar 26 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Mar 23 2015
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene Mar 20 2015
CTI BIOPHARMA CORP Financials Mar 19 2015
Small Biotech Firm Quietly Makes +1,000% Price Move Mar 17 2015
3 Stocks Near 52-Week Lows to Buy Now - Analyst Blog Mar 16 2015
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With... Mar 16 2015
CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With... Mar 16 2015
3 Biotech Stocks on Traders' Radars: Technical Charts Mar 13 2015
CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing Mar 13 2015
CTI BioPharma reports 4Q loss Mar 12 2015
CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results Mar 12 2015
CTi Biopharma Corp Earnings Call scheduled for 4:30 pm ET today Mar 12 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Mar 12 2015
CTI BIOPHARMA CORP Files SEC form 10-K, Annual Report Mar 12 2015
CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK